Financial Ratios Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 17/01/2025 GMT			5-day change	1st Jan Change
1,509.50 ^DKK	-1.05%		-6.10%	+1.14%

01-14	Genmab A/S Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 03:00 PM
01-02	A poor 2024 increases the odds of a brighter 2025

f0fb3f79276e88a349a1dd145ae09e3.nmeYk2moGrga0_M2ErQph0UqTqS9f02kEceRM2eStw8.1QLSp173Y4xQtbBga8BvwB1afZeIKQvIPK79dC703Xv_Dt_aM8xF_lShpg

Published financial data: GENMAB A/S

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	5.37B	10.11B	8.48B	14.6B	16.47B
Total Revenues	5.37B	10.11B	8.48B	14.6B	16.47B
Cost of Goods Sold, Total	-	-	-	-	226M
Gross Profit	5.37B	10.11B	8.48B	14.6B	16.25B
Selling General & Admin Expenses, Total	342M	661M	1.28B	2.68B	3.3B
R&D Expenses	2.39B	3.12B	4.18B	5.52B	7.63B
Other Operating Expenses, Total	2.73B	3.78B	5.46B	8.2B	10.93B
Operating Income	2.64B	6.34B	3.02B	6.4B	5.32B
Interest Expense, Total	-7M	-10M	-13M	-21M	-27M
Interest And Investment Income	120M	184M	197M	324M	939M
Net Interest Expenses	113M	174M	184M	303M	912M
Currency Exchange Gains (Loss)	99M	-1.46B	1.47B	1.03B	-889M
Other Non Operating Income (Expenses)	-	-	-	-	-
EBT, Excl. Unusual Items	2.85B	5.05B	4.67B	7.73B	5.34B
Gain (Loss) On Sale Of Investments	9M	873M	-689M	-659M	293M
Asset Writedown	-	-22M	-	-38M	-
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	2.86B	5.9B	3.98B	7.04B	5.64B
Income Tax Expense	693M	1.15B	975M	1.51B	1.28B
Earnings From Continuing Operations	2.17B	4.76B	3.01B	5.52B	4.35B
Net Income to Company	2.17B	4.76B	3.01B	5.52B	4.35B
Net Income - (IS)	2.17B	4.76B	3.01B	5.52B	4.35B
Net Income to Common Incl Extra Items	2.17B	4.76B	3.01B	5.52B	4.35B
Net Income to Common Excl. Extra Items	2.17B	4.76B	3.01B	5.52B	4.35B
Per Share Items
Net EPS - Basic	34.4	73	46	84.45	66.64
Basic EPS - Continuing Operations	34.4	73	46	84.45	66.64
Basic Weighted Average Shares Outstanding	62.96M	65.18M	65.4M	65.39M	65.31M
Net EPS - Diluted	34.03	72.21	45.54	83.65	66.02
Diluted EPS - Continuing Operations	34.03	72.21	45.54	83.65	66.02
Diluted Weighted Average Shares Outstanding	63.64M	65.89M	66.05M	66.01M	65.91M
Normalized Basic EPS	28.29	48.45	44.65	73.91	51.14
Normalized Diluted EPS	27.99	47.93	44.21	73.21	50.67
American Depositary Receipts Ratio (ADR)	0.1	0.1	0.1	0.1	0.1
Supplemental Items
EBITDA	2.78B	6.56B	3.27B	6.72B	5.56B
EBITA	2.74B	6.44B	3.1B	6.46B	5.38B
EBIT	2.64B	6.34B	3.02B	6.4B	5.32B
EBITDAR	2.78B	6.57B	3.27B	-	-
Effective Tax Rate - (Ratio)	24.24	19.41	24.48	21.51	22.8
Current Domestic Taxes	444M	1.19B	968M	1.5B	-
Total Current Taxes	444M	1.19B	968M	1.5B	1.3B
Deferred Domestic Taxes	249M	-45M	7M	15M	-
Total Deferred Taxes	249M	-45M	7M	15M	-16M
Normalized Net Income	1.78B	3.16B	2.92B	4.83B	3.34B
Interest on Long-Term Debt	7M	10M	13M	21M	27M
Supplemental Operating Expense Items
General and Administrative Expenses	342M	661M	-	-	-
Research And Development Expense From Footnotes	2.39B	3.14B	4.18B	5.56B	7.63B
Net Rental Expense, Total	6M	3M	1M	-	-
Imputed Operating Lease Interest Expense	-	960K	280K	-	-
Imputed Operating Lease Depreciation	-	2.04M	720K	-	-
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., Other (Total)	147M	200M	310M	439M	586M
Total Stock-Based Compensation	147M	200M	310M	439M	586M

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	3.55B	7.26B	8.96B	9.89B	14.87B
Short Term Investments	7.42B	8.82B	10.38B	12.43B	13.27B
Total Cash And Short Term Investments	10.97B	16.08B	19.34B	22.32B	28.14B
Accounts Receivable, Total	2.99B	2.46B	3.37B	5.91B	4.95B
Other Receivables	-	249M	31M	143M	-
Total Receivables	2.99B	2.71B	3.4B	6.05B	4.95B
Inventory	-	-	-	-	57M
Total Current Assets	13.96B	18.79B	22.74B	28.38B	33.14B
Gross Property Plant And Equipment	631M	1B	1.34B	1.82B	2.32B
Accumulated Depreciation	-217M	-264M	-368M	-495M	-676M
Net Property Plant And Equipment	414M	736M	975M	1.32B	1.64B
Long-term Investments	149M	1.08B	371M	133M	134M
Other Intangibles, Total	470M	338M	254M	146M	101M
Accounts Receivable Long-Term	11M	20M	27M	48M	62M
Deferred Tax Assets Long-Term	139M	177M	264M	252M	212M
Total Assets	15.14B	21.14B	24.63B	30.28B	35.29B
Liabilities
Accounts Payable, Total	-	-	350M	-	-
Accrued Expenses, Total	-	-	296M	-	-
Current Portion of Leases	26M	42M	62M	74M	90M
Current Income Taxes Payable	73M	-	-	-	54M
Unearned Revenue Current, Total	-	26M	26M	33M	33M
Other Current Liabilities	839M	1.18B	834M	1.72B	2.31B
Total Current Liabilities	938M	1.25B	1.57B	1.82B	2.48B
Long-Term Leases	155M	277M	363M	523M	680M
Unearned Revenue Non Current	-	487M	487M	480M	480M
Other Non Current Liabilities	3M	5M	13M	11M	35M
Total Liabilities	1.1B	2.02B	2.43B	2.84B	3.68B
Common Stock, Total	65M	66M	66M	66M	66M
Additional Paid In Capital	11.76B	11.89B	12.03B	12.31B	12.46B
Retained Earnings	2.13B	7.11B	10.02B	14.97B	19.02B
Comprehensive Income and Other	98M	54M	81M	98M	60M
Total Common Equity	14.05B	19.12B	22.2B	27.44B	31.61B
Total Equity	14.05B	19.12B	22.2B	27.44B	31.61B
Total Liabilities And Equity	15.14B	21.14B	24.63B	30.28B	35.29B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	64.91M	65.41M	65.43M	65.37M	65.33M
ECS Total Common Shares Outstanding	64.91M	65.41M	65.43M	65.37M	65.33M
Book Value / Share	216.42	292.31	339.23	419.77	483.85
Tangible Book Value	13.58B	18.78B	21.94B	27.3B	31.51B
Tangible Book Value Per Share	209.18	287.14	335.35	417.54	482.3
Total Debt	181M	319M	425M	597M	770M
Net Debt	-10.79B	-15.76B	-18.91B	-21.73B	-27.36B
Debt Equivalent Oper. Leases	48M	24M	8M	-	-
Account Code - Inventory Valuation	3	3	3	3	3
Inventories - Raw Materials, Total	-	-	-	-	14M
Inventories - Finished Goods, Total	-	-	-	-	59M
Machinery, Total	279M	416M	537M	649M	908M
Full Time Employees	548	781	1.21K	1.66K	2.2K

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	2.17B	4.76B	3.01B	5.52B	4.35B
Depreciation & Amortization - CF	88M	157M	220M	328M	185M
Amortization of Goodwill and Intangible Assets - (CF)	99M	109M	84M	70M	55M
Depreciation & Amortization, Total	187M	266M	304M	398M	240M
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-9M	-873M	689M	659M	-293M
Asset Writedown & Restructuring Costs	-	29M	-	38M	-
Stock-Based Compensation (CF)	147M	200M	310M	439M	586M
Other Operating Activities, Total	53M	1.07B	-1.31B	-1.21B	1.13B
Change In Accounts Receivable	-1.66B	306M	-1.07B	-2.21B	797M
Change In Inventories	-	-	-	-	-57M
Change In Accounts Payable	440M	168M	304M	283M	622M
Change in Unearned Revenues	-	513M	-	-	-
Change in Other Net Operating Assets	-	-	-	-	-
Cash from Operations	1.33B	6.43B	2.23B	3.91B	7.38B
Capital Expenditure	-79M	-307M	-252M	-317M	-366M
Sale of Property, Plant, and Equipment	-	-	-	-	-
Sale (Purchase) of Intangible assets	-32M	-	-	-	-10M
Investment in Marketable and Equity Securities, Total	-1.87B	-2.04B	-709M	-2.44B	-906M
Cash from Investing	-1.98B	-2.35B	-961M	-2.76B	-1.28B
Long-Term Debt Repaid, Total	-31M	-44M	-58M	-73M	-91M
Total Debt Repaid	-31M	-44M	-58M	-73M	-91M
Issuance of Common Stock	3.94B	140M	135M	280M	152M
Repurchase of Common Stock	-9M	-25M	-497M	-996M	-667M
Other Financing Activities, Total	-238M	-	-	-	-
Cash from Financing	3.66B	71M	-420M	-789M	-606M
Foreign Exchange Rate Adjustments	16M	-445M	850M	574M	-518M
Net Change in Cash	3.02B	3.71B	1.7B	936M	4.97B
Supplemental Items
Cash Interest Paid	20M	20M	12M	16M	25M
Cash Income Tax Paid (Refund)	476M	1.48B	742M	1.58B	1.07B
Levered Free Cash Flow	672M	4.69B	1.85B	2.09B	5.29B
Unlevered Free Cash Flow	677M	4.7B	1.86B	2.1B	5.31B
Change In Net Working Capital	1.2B	-577M	391M	2.41B	-1.54B
Net Debt Issued / Repaid	-31M	-44M	-58M	-73M	-91M

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	13.97	21.82	8.24	14.56	10.17
Return on Total Capital	14.82	23.52	8.97	15.78	11.04
Return On Equity %	19.64	28.69	14.56	22.25	14.78
Return on Common Equity	19.64	28.69	14.56	22.25	14.78
Margin Analysis
Gross Profit Margin %	100	100	100	100	98.63
SG&A Margin	6.37	6.54	15.13	18.34	20.01
EBITDA Margin %	51.75	64.93	38.5	46.04	33.76
EBITA Margin %	51.01	63.73	36.57	44.3	32.63
EBIT Margin %	49.16	62.65	35.58	43.82	32.3
Income From Continuing Operations Margin %	40.37	47.06	35.46	37.83	26.42
Net Income Margin %	40.37	47.06	35.46	37.83	26.42
Net Avail. For Common Margin %	40.37	47.06	35.46	37.83	26.42
Normalized Net Income Margin	33.2	31.23	34.43	33.11	20.27
Levered Free Cash Flow Margin	12.53	46.38	21.8	14.33	32.13
Unlevered Free Cash Flow Margin	12.61	46.44	21.9	14.42	32.24
Asset Turnover
Asset Turnover	0.45	0.56	0.37	0.53	0.5
Fixed Assets Turnover	18.63	17.58	9.91	12.71	11.12
Receivables Turnover (Average Receivables)	2.49	3.71	2.91	3.15	3.09
Short Term Liquidity
Current Ratio	14.88	15	14.5	15.57	13.34
Quick Ratio	14.88	15	14.5	15.57	13.32
Operating Cash Flow to Current Liabilities	1.41	5.13	1.42	2.15	2.97
Days Sales Outstanding (Average Receivables)	146.82	98.69	125.44	116	118.08
Long Term Solvency
Total Debt/Equity	1.29	1.67	1.91	2.18	2.44
Total Debt / Total Capital	1.27	1.64	1.88	2.13	2.38
LT Debt/Equity	1.1	1.45	1.64	1.91	2.15
Long-Term Debt / Total Capital	1.09	1.42	1.6	1.87	2.1
Total Liabilities / Total Assets	7.24	9.56	9.87	9.37	10.43
EBIT / Interest Expense	376.86	633.5	232.15	304.52	197.07
EBITDA / Interest Expense	403.57	660.1	255.54	323.48	205.96
(EBITDA - Capex) / Interest Expense	392.29	629.4	236.15	308.38	192.41
Total Debt / EBITDA	0.06	0.05	0.13	0.09	0.14
Net Debt / EBITDA	-3.82	-2.39	-5.69	-3.2	-4.92
Total Debt / (EBITDA - Capex)	0.07	0.05	0.14	0.09	0.15
Net Debt / (EBITDA - Capex)	-3.93	-2.5	-6.16	-3.36	-5.27
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	77.39	88.43	-16.11	72.07	13.57
Gross Profit, 1 Yr. Growth %	77.39	88.43	-16.11	72.07	12.02
EBITDA, 1 Yr. Growth %	89.17	136.41	-50.25	105.73	-14.72
EBITA, 1 Yr. Growth %	90.07	135.44	-51.86	108.41	-15.67
EBIT, 1 Yr. Growth %	91.16	140.14	-52.36	111.9	-15.61
Earnings From Cont. Operations, 1 Yr. Growth %	47.15	119.67	-36.78	83.58	-20.18
Net Income, 1 Yr. Growth %	47.15	119.67	-36.78	83.58	-20.18
Normalized Net Income, 1 Yr. Growth %	75.6	77.3	-7.54	65.5	-30.07
Diluted EPS Before Extra, 1 Yr. Growth %	43.4	112.2	-36.93	83.68	-20.06
Accounts Receivable, 1 Yr. Growth %	125.32	-17.63	36.7	75.53	-13.39
Net Property, Plant and Equip., 1 Yr. Growth %	155.56	77.78	32.47	35.59	24.13
Total Assets, 1 Yr. Growth %	78.99	39.61	16.48	22.95	17.17
Tangible Book Value, 1 Yr. Growth %	79.98	38.33	16.82	24.4	16.12
Common Equity, 1 Yr. Growth %	75.29	36.11	16.08	23.63	15.86
Cash From Operations, 1 Yr. Growth %	30.64	385.14	-65.37	75.58	88.65
Capital Expenditures, 1 Yr. Growth %	9.72	288.61	-17.92	25.79	15.46
Levered Free Cash Flow, 1 Yr. Growth %	-6.87K	618.78	-60.57	13.12	163.04
Unlevered Free Cash Flow, 1 Yr. Growth %	-6.91K	614.94	-60.45	13.33	162.17
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	50.62	82.82	25.73	20.14	39.9
Gross Profit, 2 Yr. CAGR %	50.62	82.82	25.73	20.14	38.94
EBITDA, 2 Yr. CAGR %	40.14	111.47	8.45	1.34	32.93
EBITA, 2 Yr. CAGR %	39.74	111.54	6.46	0.33	33.05
EBIT, 2 Yr. CAGR %	38.95	114.26	6.96	0.65	34.23
Earnings From Cont. Operations, 2 Yr. CAGR %	40.1	79.79	17.84	7.73	21.32
Net Income, 2 Yr. CAGR %	40.1	79.79	17.84	7.73	21.32
Normalized Net Income, 2 Yr. CAGR %	60.56	76.45	28.04	23.97	7.7
Diluted EPS Before Extra, 2 Yr. CAGR %	38.38	74.44	15.68	7.63	21.44
Accounts Receivable, 2 Yr. CAGR %	127.25	36.24	6.12	54.9	21.21
Net Property, Plant and Equip., 2 Yr. CAGR %	91.06	113.15	53.46	34.02	29.73
Total Assets, 2 Yr. CAGR %	51.44	58.08	27.52	19.67	19.71
Tangible Book Value, 2 Yr. CAGR %	48.61	57.79	27.12	20.55	19.83